Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB27 vs Keytruda in Metastatic Non-squamous NSCLC
NCT06348199Phase 3Active, not recruiting
- Sponsor
- Samsung Bioepis
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of QL2107 in non-small cell lung cancer (NSCLC), sponsored by Samsung Bioepis. Started Mar 2024; status: active, not recruiting.
02
Drugs
QL2107
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06348199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06348199.